Combining segments 9 and 10 in DNA and recombinant protein vaccines conferred superior protection against tilapia lake virus in hybrid red tilapia (oreochromis sp.) compared to single segment vaccines

• DOI: 10.3389/fimmu.2022.935480
• Publication Date: 2022-07-25T13:38:35Z
• Authors: Pitakthai Chamtim; Eukote Suwan; Ha Thanh Dong; Soranuth Sirisuay; Nontawith Areechon; Eakapol Wangkahart; Ikuo Hirono; Rapeepat Mavichak; Sasimanas Unajak
• Keywords: DNA vaccine; Vaccine Design; Immunology; TiLV ORF9; Prediction of Peptide-MHC Binding Affinity; DNA vaccination; Microbiology; Gene; Biochemistry; Agricultural and Biological Sciences; TiLV; Fish Diseases; 03 medical and health sciences; Biochemistry, Genetics and Molecular Biology; Virology; TiLV ORF10; Animals; Nile tilapia; Viral Diseases in Livestock and Poultry; Molecular Biology; Biology; Antibody; Immunological Responses in Aquatic Organisms; Immunology and Microbiology; Vaccines, Synthetic; 0303 health sciences; Recombinant DNA; Oreochromis; FOS: Clinical medicine; Vaccination; recombinant protein vaccine; Life Sciences; Cichlids; DNA; RC581-607; Virus; 3. Good health; tilapia (fish); Fish; Fishery; FOS: Biological sciences; Viruses; Animal Science and Zoology; Immunologic diseases. Allergy; Tilapia

Tilapia lake virus (TiLV) now affects Nile tilapia culture worldwide, with no available commercial vaccine for disease prevention. DNA and recombinant protein-based vaccines were developed tested following viral isolation characterization. The strain isolated from diseased hybrid red (